Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fusion Antibodies Plc ( (GB:FAB) ) has provided an update.
Fusion Antibodies plc has confirmed that its issued share capital consists of 125,021,878 ordinary shares of 4 pence each, all carrying one voting right and with none held in treasury, establishing the total number of voting rights currently in the company. This figure provides the reference denominator for shareholders to assess and report any notifiable holdings or changes in their interests under UK disclosure and transparency rules, offering clarity on the company’s capital structure and supporting regulatory compliance for investors.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £13.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc’s overall stock score is primarily impacted by its weak financial performance and concerning valuation. While there is some technical momentum, the negative P/E ratio and lack of profitability are significant risks. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Northern Ireland-based contract research organisation specialising in pre-clinical antibody discovery, engineering and expression services across human and veterinary therapeutics as well as diagnostic applications. The company offers an integrated end-to-end suite of services, including antibody discovery, development, characterisation, optimisation, small-scale production, antigen design and expression, antibody purification and sequencing, and cell line development, underpinned by proprietary platforms such as CDRx, OptiMAL and OptiPhage. Serving an international client base that includes leading global pharmaceutical companies, Fusion targets the rapidly expanding antibody therapeutics market, while also pursuing opportunities in diagnostic and veterinary sectors.
Average Trading Volume: 843,244
Technical Sentiment Signal: Buy
Current Market Cap: £14.92M
For an in-depth examination of FAB stock, go to TipRanks’ Overview page.